Navigation Links
Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
Date:6/9/2008

- Dimebon Showed Statistically Significant Benefit Versus Placebo on All

Key Efficacy Endpoints in First Pivotal Trial -

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced it has initiated dosing of patients in its second pivotal Phase 3 trial of the investigational drug Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease (AD). The international, double-blind, placebo-controlled safety and efficacy study of oral Dimebon is known as the CONNECTION study.

"We saw very encouraging results in our first pivotal trial, in which Dimebon demonstrated statistically significant improvements over placebo on all five efficacy endpoints at both six months and at one year. We look forward to confirming the efficacy and safety of Dimebon in the CONNECTION study," said Lynn Seely, M.D., Chief Medical Officer of Medivation. "The initiation of this study brings us a major step closer to our goal of obtaining regulatory approval for Dimebon. We are working to bring this investigational drug to market as quickly as possible to address the unmet medical need in Alzheimer's disease and bring hope to patients and caregivers."

The U.S. Food and Drug Administration (FDA) has informed Medivation that the CONNECTION study together with the previously completed pivotal trial can be used to support the approval of Dimebon to treat mild-to-moderate Alzheimer's disease, as long as a significant proportion of the sites in the CONNECTION study are located in the United States. Medivation expects to complete the CONNECTION study and apply for U.S. and European marketing approval in 2010.

Design of CONNECTION Study

The CONNECTION study will enroll approximately 525 p
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
4. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
5. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
6. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
7. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
8. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
11. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Hologic, Inc. (NASDAQ: HOLX ) today announced ... 28, 2014. Third Quarter Financial Highlights and ... million, reflecting operational growth of 0.5% and a positive ... in the prior year. , Revenues grew in ... revenues grew 3.5%. , GYN Surgical revenues grew ...
(Date:7/30/2014)... July 30, 2014  Cepheid (Nasdaq: ... contract with Premier will end on September 30, ... will be able to continue their relationship with ... MedAssets, Novation, and ROi, in addition to the ... Cepheid. "Cepheid has always recognized and ...
(Date:7/30/2014)... , July 30, 2014 CryoLife, Inc. (NYSE: ... focused on cardiac and vascular surgery, announced today that ... dividend for the third quarter 2014 of $0.03 per ... of $0.03 per share will be paid on September ... of September 12, 2014.  The ex-dividend date for the ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3
...  19, 2011 The Emergency Medicine Patient Safety ... upcoming 1st Annual Patient Safety Summit in Las Vegas, ... Safety in Emergency Care: Excellence in Outcomes, (Twitter ... on solving the patient safety challenges associated with providing ...
... 19, 2011 Medical Care Technologies Inc. ... industry, is pleased to announce that is has signed ... Limited ("OWII"), a private Hong Kong investment holding company ... opening and operating private pediatric clinics throughout China. ...
Cached Medicine Technology:National Leaders in Emergency Medicine and Patient Safety to Address Future Opportunities and Challenges in Emergency Care 2Medical Care Technologies Inc. Signs Letter of Intent for Joint Venture in China 2Medical Care Technologies Inc. Signs Letter of Intent for Joint Venture in China 3
(Date:7/30/2014)... (PRWEB) July 30, 2014 Volunteers from ... to counter drug abuse this summer with massive distribution ... , You can find these volunteers on Strøget, the ... residents alike for its shopping and its ambiance, some ... on a typical summer day. , These activities ...
(Date:7/30/2014)... Hawley, Pennsylvania (PRWEB) July 30, 2014 ... and have contributed over $8,500 to ensure its protection. ... Resort, presents a check to the Delaware Highlands Conservancy ... Partnership program. The small $2-per-stay donations add up fast, ... future of the Upper Delaware River Region. , The ...
(Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
(Date:7/30/2014)... OR (PRWEB) July 30, 2014 LTC Consumer, ... evaluate long term care insurance, features an Instant Quote tool ... Director and co-founder of LTC Consumer. Quotes are free and ... a click in only seven areas – including age, gender, ... on screen within seconds (you don’t need to enter any ...
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 The ... nutrition school, is pleased to announce that Arianna Huffington has ... the curriculum of the Health Coach Training Program . ... The Huffington Post, a world-renowned news and blogging site that ... is the author of fourteen books and was included on ...
Breaking Medicine News(10 mins):Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3
... development collaboration between leading Australian Institutions, the Children,s ... of Melbourne and Bio-Link Partners Ltd., has been ... New Therapy Grant winners. This prestigious research grant ... focussed on development and commercialisation of small molecule ...
... to other parts of the body, known as metastasis, is ... cancer. Although patients with early stage, small, breast tumours have ... per cent of them will eventually develop distant metastases, and ... blood vessels is the major route for cancer spreading ...
... DATATRAK International,Inc. (Nasdaq: DATA ), a technology ... the clinical trials industry, today announced that,it received ... Nasdaq Stock Market,("Nasdaq"), notifying the Company that for ... 2008, the bid price of the Company,s common ...
... HighPoint Solutions LLC,a premier provider of ... signed an agreement with a global specialty ... N Managed Care and Government Pricing,System., ... finding,systematic approaches to effectively comply with government ...
... announced a $100 million (AUD) initiative to build ... assist in discovering cures and therapies for such ... ,flu pandemics. , In making the announcement at ... Diego, Premier Brumby said the Victorian government is ...
... Live Call-ins, Interactive Blogs on Topics From Holistic Health to ... ... RATON, Fla., June 18 BocaRaton.com and The Bites!,Network will ... "The Insight" featuring three hosts who will,discuss various topics dealing ...
Cached Medicine News:Health News:Dynamin drug discovery team win prestigious international epilepsy grant 2Health News:Dynamin drug discovery team win prestigious international epilepsy grant 3Health News:Improving understanding of cell behavior in breast cancer 2Health News:DATATRAK International, Inc. Receives Notice From Nasdaq 2Health News:DATATRAK International, Inc. Receives Notice From Nasdaq 3Health News:HighPoint Solutions Signs Deal to Implement Model N Managed Care and Government Pricing System for Specialty Pharmaceutical Company 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 3Health News:A South Florida Premiere 2
BD Visitec IOL Manipulator (Fenzl), blunt tip angled 45, 12.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge ind...
... IOL Manipulator (Jaffe-Maltzman), blunt tip, ... end, fits 0.20 mm diameter ... intraocular lenses, (3/bx, 1 bx/ca), ... Sure grip handles hand ridge ...
Sinskey lens manipulator, straight. Also available in titanium....
Straight, with guard. Ideal for multi-directional manipulation....
Medicine Products: